Genmab — Januar 2017

[E_L]

Sebia signs agreement with Janssen Biotech to develop a multiple myeloma IVD test http://www.ala.com/sebia-signs-agreement-with-janssen-biotech-to-develop-a-multiple-myeloma-ivd-test/

[E_L]

If I understand correctly, this should help monitor patients blood that are on darzalex, limiting the bloodbank problem?

[Solsen]

No sure it solves that limited issue. You dont get false results on M-protein with the new test.

[E_L]

think you are correct, probable meant to test patients response to treatment and measure level of illness

[bibob]

January 28. 2017 The J.P.Morgan Chase & CO upgrades Genmab A/S (GNMSF) to overweight.

[E_L]

they upgraded Genmab earlier this month i believe, this just a follow up for the other symbols it trades under. They should just delist GNMSF , nobody trades it there anyway...

[E_L]

Maybe they can upgrade GMXAY tomorrow

[bibob]

Yes it would be much better.

[Helge_LarsenPI-redaktør]

Overskrifter vi kan lide ligesom betegnelsen "defensiv aktie". http://penge.borsen.dk/artikel/1/339167/aktier_genmab_satte_igen_rekord_i_roedt_marked.html

[bibob]

Ja Helge. Lad det bare være en defensiv aktie. Især når den er i offensiven.

[pauly]

Der er flere som kalder den defensiv, det forstår jeg godt nok ikke, det rimer sku ikke rigtigt

[dohk]

Så er Roche's anti cd20 ved at nå målet i MS http://www.fiercepharma.com/special-report/1-ocrevus

[dohk]

med et forventet peaksalg på $4mia i 2022. Det bliver spænende om Genmabs subkutane version bliver en reel konkurrent, eller first in class bliver afgørende igen.

[LyngeInv]

Defensiv fordi den ikke er cyklist = konjukturafhængig.. :)... Solgt ud af alle aktier idag - tror Trump får skabt meget nervøsitet i kommende tid.. og ingen ved, hvad han finder på, når pharma lander på hans agenda... går sikkert fri at det opløb der teknisk set står her efter 1300 ... men synes der er stor risiko i øjelblikket...

[pauly]

Hvor længe skal genmabs cd20 køre fase3
i ms?

[Nickstar]

Er næste trigger årsregnskabet? Med mindre der kommer uventede positive nyheder

[gentogen]

A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy.

[gentogen]

M.D.Anderson:Neoadjuvant Listeria or Daratumumab in Prostate Cancer.https://clinicaltrials.gov/ct2/show/NCT03035357?term=daratumumab&rank=1

[gentogen]

A Study to Investigate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab Combination Therapy in Virus-associated Tumors.

[gentogen]

nivolumab in combination with ipilimumab, BMS-986016 or daratumumab in human subjects who have the following types of tumors: Epstein Barr Virus (EBV) positive gastric cancer; EBV positive nasopharyngeal cancer (NPC); Human Papilloma Virus (HPV) positive cervical, vaginal, vulvar cancer; Other HPV-associated tumors (anal canal, penile), HPV positive squamous cell cancer of the head and neck (SCCHN); and Polyomavirus positive merkel cell cancer